Because blood is so easy to sample, scientists like to screen this biofluid when looking for disease associations. Alas, that is not the best approach for neurodegenerative disorders, according to ...

Scientists already suspect that somatic mutations—those that accrue in cells outside the germline over a person’s lifetime, seemingly at random—play a role in neurodegenerative diseases. Now, several ...

Sensory Stimulation Systems, and GENUS, refer to a noninvasive procedure, i.e., a "digital therapeutic," being developed by Cognito Therapeutics. The company developed a wearable GammaSense ...

As mountains of multimodal data grow in quantity and complexity, artificial intelligence is being touted as a way to extract insight and better therapies from them. At this year’s AD/PD conference, ...

People who consume copious fruits and vegetables tend to enjoy healthier, longer lives, and are less prone to dementia. How could noshing on plants ward off age-related diseases such as Alzheimer’s?

Exercise helps stave off Alzheimer’s disease, but exactly how it does so is murky. In the February 18 Cell, scientists led by Saul Villeda at the University of California, San Francisco, offered one ...

Post-marketing data chart immunotherapy performance in early-onset Alzheimer’s. The antibodies lowered amyloid and slowed functional decline. However, tangles continued to form. “These results offer ...

If a person with no cognitive complaints tests positive for brain amyloid based on plasma p-tau217, what should their doctor tell them about their likelihood of getting Alzheimer’s disease? That’s the ...

The world did not end today as predicted, but unfortunately we have to report that development of another potential drug did. Allon Therapeutics Inc. announced 19 December that its drug candidate ...

Amyloid immunotherapies are here, but inflammaging remains a powerful driver of neurodegenerative disease. Neuroinflammation is a rich, but thus far quite elusive, source of new drug targets. Some ...

Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...

The current Alzheimer’s disease therapeutic antibodies carry a sizable risk of ARIA, especially for APOE4 carriers. Researchers believe the future of amyloid immunotherapies lies in targeted brain ...